Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Flexible Stenting Solutions has submitted an investigational device exemption, or IDE, application to the FDA for its FlexStent femoropopliteal self-expanding stent system for the treatment of peripheral artery disease in the superficial femoral and popliteal arteries.
Subscribe to our email newsletter
According to Flexible Stenting Solutions, this next-generation femoropopliteal stent and delivery system can significantly improve patient care in the high growth peripheral vascular segment. The fully connected flexible FlexStent has coupled technology with clinical needs by providing a highly durable and fatigue-resistant stent, the company said.
The FlexStent reportedly has superior radial stiffness, as well as excellent conformability to and mobility with the treated vessel. The delivery system provides simplicity, ease-of-use and accurate, uniform stent placement for the vascular interventionalist, the company added.
Janet Burpee, CEO of Flexible Stenting Solutions, said: “We believe the FlexStent represents a true third-generation femoropopliteal stent and delivery system that can significantly improve clinical outcomes in this hard to treat area.”